ZymoGenetics
From Wikipedia, the free encyclopedia
ZymoGenetics is a biotechnology/pharmaceutical company based in Seattle, Washington involved in the development of therapeutic proteins.
The company was founded in 1981 by Professors Earl W. Davie and Benjamin D. Hall of the University of Washington and 1993 Nobel Laureate in Chemistry Michael Smith of the University of British Columbia. Soon after its founding, ZymoGenetics began working on recombinant proteins with Denmark's Novo Nordisk, and was acquired by that company in 1988. It was spun off as a public company in 2000, and its shares trade on the NASDAQ stock market under the ticker symbol ZGEN.
ZymoGenetics' headquarters are in the landmark Lake Union Steam Plant building, built from 1914 to 1921 by Seattle City Light, the municipal electric utility.
[edit] External links
- http://www.zymogenetics.com/
- Worldwide Patent Search in European Patent Office Database for ZymoGenetics
- List of Patents from United States Patent and Trademark Office for ZymoGenetics
 |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
